Abstract
The evidence to date does not justify the administration of bicarbonate for the emergent treatment of diabetic ketoacidosis (DKA), especially in the pediatric population, in view of possible clinical harm and lack of sustained benefits.
Introduction
Diabetic ketoacidosis (DKA) is a life-threatening complication of diabetes characterized by severe metabolic acidosis. Historically, clinicians followed a "physiological paradigm": since severe acidemia can impair heart contractility and enzyme function, neutralizing the acid with intravenous bicarbonate should, in theory, stabilize the patient. However, this practice has long been controversial. While it makes sense on paper, clinical observations suggested that bicarbonate might trigger a "paradoxical" worsening of certain symptoms. This paper addresses the gap between physiological theory and clinical reality by systematically reviewing 50 years of literature to determine if bicarbonate therapy is truly efficacious or if it does more harm than good.
Methodology and Study Selection
The authors performed a systematic review of the PubMed database, identifying 508 potentially relevant articles published between 1960 and 2010. Two reviewers independently extracted data to ensure objectivity, focusing on Randomized Controlled Trials (RCTs), case-control studies, and pediatric-specific outcomes like cerebral edema (CE).
Evidence Base
The review ultimately included 44 articles, comprising:
- 3 Randomized Controlled Trials (RCTs): All conducted in adults, totaling only 73 patients.
- 9 Non-randomized/Retrospective studies: Covering both adults and children.
- 4 Pediatric studies: Specifically investigating the link between bicarbonate and cerebral edema.
- 14 Case reports/series: Documenting specific clinical experiences.
Notably, the authors found zero RCTs performed in the pediatric population, highlighting a significant data gap in the most vulnerable group.
Key Clinical Insights
The Paradoxical Effect
One of the most striking insights is that bicarbonate can actually worsen acidosis in the brain. While it raises blood pH, it can cause a "paradoxical" drop in cerebrospinal fluid (CSF) pH because $CO_2$ (a byproduct of the treatment) crosses the blood-brain barrier much faster than the bicarbonate itself.
Delayed Recovery and Potassium Shifts
Instead of speeding up recovery, evidence suggests bicarbonate may slow the decline of blood ketones and prolong the need for hospitalization. Furthermore, bicarbonate administration shifts potassium from the blood into the cells. Without aggressive monitoring, this can lead to dangerous hypokalemia (low blood potassium).
The "pH Floor"
The review found that no studies included patients with an initial pH below 6.85. This means that for the most extreme, near-death cases of DKA, there is essentially no high-quality evidence to guide treatment.
Key Results and Outcomes
The systematic review found no evidence of a sustained clinical edge for bicarbonate therapy. While some studies noted a transient improvement in blood pH within the first two hours, there was no difference in the time required to reach a stable pH of 7.3 or in overall glycemic control.
In pediatric populations, the risks were even more pronounced. One study reported that children receiving bicarbonate stayed in the hospital significantly longer (87 hours vs. 67 hours, $p=0.01$). Most critically, bicarbonate therapy was identified as a major risk factor for cerebral edema (CE), with one study reporting a relative risk of 4.2 for children treated with the alkali.
Limitations and Future Directions
The primary limitation of this review is the small sample size of existing high-quality trials. With only 73 patients across three adult RCTs, the statistical power to detect differences in mortality is low. Furthermore, the exclusion of patients with pH < 6.85 from most studies leaves the "most severe" category of DKA as an evidence-free zone.
The authors suggest that future research should move away from simple bicarbonate boluses and instead investigate balanced electrolyte solutions with better buffering capacity. Given the risk of cerebral edema, the authors strongly advise against routine use in children until safer protocols are established.
Summary updated